Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs Methotrexate in MTX-Naïve RA (SELECT-EARLY)
NCT02706873Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 45
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (4 arms), sponsored by AbbVie Inc. Primary endpoints: American College of Rheumatology 50% Response at 12 weeks, Clinical Remission based on DAS28(CRP) at 24 weeks and 2 more. Started Feb 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02706873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706873.